Aptevo Therapeutics shares crashed 45% to an all-time low after the company approved a 1-for-18 reverse stock split to regain Nasdaq listing compliance. The move cuts outstanding shares from about 18 million to roughly one million, with split-adjusted trading starting December 30. Shareholders had previously authorised a split ratio of 1-for-6 to 1-for-20.